A Stanford-led team has replaced toxic pre-transplant chemotherapy with a targeted antibody, allowing children with Fanconi anemia to receive stem cell transplants safely. The antibody, briquilimab, removes diseased stem cells without radiation, enabling nearly complete donor cell replacement. The approach also widens donor eligibility and could soon be applied to other bone marrow failure diseases.
Source:
Read full article at www.sciencedaily.com
Medical Disclaimer:
This content is for informational and educational purposes only.
It does not replace professional medical advice.
